Ashok Kumar P, Ramapriyadharshini J, Subhashini M
AIM Role of Interleukin-6 and HS-CRP Levels in the assessment of active thyroid eye disease.
MATERIALS & METHODS A prospective observational study of 30 patients from the age group of 20-60 years with thyroid eye disease done at Regional Institute of Ophthalmology. All patients were subjected to detailed history, ocular examination, systemic examination, biochemical analysis and Imaging. Patients are categorised as mild, moderate and severe active disease based on clinical activity score. For the period of two years, patients are followed at regular periodic intervals according to the severity of disease and results were analysed.
RESULTS Out of 30 patients studied, majority of the patients were females (60%), and 70% of the patients had bilateral disease. Among 30 patients, 83.33% in hyperthyroid state, 3.33% in Hypothyroid state, 13.33% in Euthyroid state (Table 3). Smoking being important risk factor in 30% among males. 50% of patients presented with mild disease, 30% with moderate disease, 0% with severe disease. IL-6, HS-CRP levels are increased only in patients with severe active disease (Table 6). Remission attained in all patients when treated earlier with steroids.
CONCLUSION Identifying disease activity early and aggressive treatment with systemic steroids in active phase of moderate and severe disease has reduced the morbidity associated with disease. Correlation of IL-6, HS-CRP, TFT levels are significantly increased only in patients with active phase of severe thyroid eye disease but not significantly elevated in active phase of moderate disease. Another pitfall is IL-6 is an expensive ELISA based diagnosis. Thus, IL-6 & HS-CRP cannot be routinely used to screen patients with Thyroid eye disease.
